SML2106
Roflupram
≥98% (HPLC)
Sinônimo(s):
1-[4-(Difluoromethoxy)-3-[(tetrahydro-3-furanyl)oxy]phenyl]-3-methyl-1-butanone, FFPM, ZL-n-91
Faça loginpara ver os preços organizacionais e de contrato
About This Item
Fórmula empírica (Notação de Hill):
C16H20F2O4
Número CAS:
Peso molecular:
314.32
Código UNSPSC:
12352200
Produtos recomendados
Ensaio
≥98% (HPLC)
forma
oil
cor
colorless to light brown
temperatura de armazenamento
2-8°C
cadeia de caracteres SMILES
O=C(CC(C)C)C1=CC=C(OC(F)F)C(OC2CCOC2)=C1
Ações bioquímicas/fisiológicas
Roflupram (FFPM) is a potent anti-inflammatory phosphodiesterase 4 (PDE4) inhibitor that was found to suppress inflammasome activation in microglial cells by enhancing autophagy. In microglial BV-2 cells roflupram enhanced the level of microtubule-associated protein 1 light chain 3 II (LC3-II) and decreased the autophagy receptor ubiquitin-binding protein p62 (SQSTM1), enhancing autophagy, reducing the activation of inflammasome and suppressing the production of IL-1β. Roflupram (FFPM) was found to reverse learning and memory deficits in APP/PS1 transgenic mice.
Código de classe de armazenamento
11 - Combustible Solids
Classe de risco de água (WGK)
WGK 3
Ponto de fulgor (°F)
Not applicable
Ponto de fulgor (°C)
Not applicable
Certificados de análise (COA)
Busque Certificados de análise (COA) digitando o Número do Lote do produto. Os números de lote e remessa podem ser encontrados no rótulo de um produto após a palavra “Lot” ou “Batch”.
Já possui este produto?
Encontre a documentação dos produtos que você adquiriu recentemente na biblioteca de documentos.
Hui-Fang Tang et al.
International immunopharmacology, 10(4), 406-411 (2010-01-16)
In the present study, we investigated the effect of classic PDE4 inhibitor rolipram and novel PDE4 inhibitor ZL-n-91 on LPS-induced acute lung injury (ALI) in mice and its mechanism. ALI was induced in ICR mice by instilling intratracheally with LPS
Tingting You et al.
ACS chemical neuroscience, 8(11), 2381-2392 (2017-06-13)
Inhibition of phosphodiesterase 4 (PDE4) suppressed the inflammatory responses in the brain. However, the underlying mechanisms are poorly understood. Roflupram (ROF) is a novel PDE4 inhibitor. In the present study, we found that ROF enhanced the level of microtubule-associated protein
Haibiao Guo et al.
Neuropharmacology, 116, 260-269 (2017-01-10)
Thus far, phosphodiesterase-4 (PDE4) inhibitors have not been approved for application in Alzheimer's disease (AD) in a clinical setting due to severe side effects, such as nausea and vomiting. In this study, we investigated the effect of FFPM, a novel
Shilong Zheng et al.
Journal of medicinal chemistry, 51(24), 7673-7688 (2008-12-04)
Phosphodiesterase 4 catalyzes the hydrolysis of cyclic AMP and is a target for the development of anti-inflammatory agents. We have designed and synthesized a series of phenyl alkyl ketones as PDE4 inhibitors. Among them, 13 compounds were identified as having
Dan Li et al.
International immunopharmacology, 90, 107176-107176 (2020-11-28)
Roflupram (ROF) is a novel phosphodiesterase 4 inhibitor. We previously found that ROF suppressed the production of pro-inflammatory factors in microglial cells; however, the underlying mechanisms are largely unknown. The present study aimed to elucidate the underlying molecular mechanisms of
Nossa equipe de cientistas tem experiência em todas as áreas de pesquisa, incluindo Life Sciences, ciência de materiais, síntese química, cromatografia, química analítica e muitas outras.
Entre em contato com a assistência técnica